CD8A and neoplasm: To date, ICIs that have reached the patients’ bedside have focused on releasing effector CD8+ T cells from functional restrictions induced by the tumor and its micro-environment (Topalian et al., 2015; Fesnak et al., 2016; Khalil et al., 2016).